Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Venkat Sethuraman

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Drug Discovery Today|March 20, 2024
Accelerating drug development at Bristol Myers Squibb through innovationKalyanee Viraswami-Appanna, Joan Buenconsejo, Charlotte Baidoo, et al.
Clinical Therapeutics|January 30, 2010
Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group studyOphelia Q P Yin, Neil Gallagher, Chiaki Tanaka, et al.
Journal of Clinical Pharmacology|May 17, 2017
A Systematic Review and Pooled Analysis of Select Safety Parameters Among Normal Healthy Volunteers Taking Placebo in Phase 1 Clinical TrialsTina C Young, Subasree Srinivasan, Marion L Vetter, et al.
British Journal of Clinical Pharmacology|April 4, 2008
Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemiaYanfeng Wang, Li Zhou, Catherine Dutreix, et al.
Clinical Pharmacology and Therapeutics|January 6, 2023
Emulating Randomized Controlled Trials with Hybrid Control Arms in Oncology: A Case StudySanhita Sengupta, Ives Ntambwe, Katherine Tan, et al.
Clinical Trials (London, England)|June 13, 2023
Data-driven strategies for increasing patient diversity in Bristol Myers Squibb-sponsored US oncology clinical trialsLorena Kuri, Sagar Setru, Gengyuan Liu, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Drug Discovery Today|March 20, 2024
Accelerating drug development at Bristol Myers Squibb through innovationKalyanee Viraswami-Appanna, Joan Buenconsejo, Charlotte Baidoo, et al.
Clinical Therapeutics|January 30, 2010
Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group studyOphelia Q P Yin, Neil Gallagher, Chiaki Tanaka, et al.
Journal of Clinical Pharmacology|May 17, 2017
A Systematic Review and Pooled Analysis of Select Safety Parameters Among Normal Healthy Volunteers Taking Placebo in Phase 1 Clinical TrialsTina C Young, Subasree Srinivasan, Marion L Vetter, et al.
British Journal of Clinical Pharmacology|April 4, 2008
Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemiaYanfeng Wang, Li Zhou, Catherine Dutreix, et al.
Clinical Pharmacology and Therapeutics|January 6, 2023
Emulating Randomized Controlled Trials with Hybrid Control Arms in Oncology: A Case StudySanhita Sengupta, Ives Ntambwe, Katherine Tan, et al.
Clinical Trials (London, England)|June 13, 2023
Data-driven strategies for increasing patient diversity in Bristol Myers Squibb-sponsored US oncology clinical trialsLorena Kuri, Sagar Setru, Gengyuan Liu, et al.
Pageof 2